PureTech Secures Orphan Drug Designation for LYT-100, Advancing New Treatment Development

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Feb 19 2026

0mins

PRTC+0.36%

Should l Buy PRTC?

Source: Newsfilter

Orphan Drug Designation: PureTech Health announced that its LYT-100 has received Orphan Drug Designation from both the FDA and the European Commission, aimed at facilitating the development of therapies for rare diseases, highlighting the urgent need for effective treatments in this patient population.
Clinical Trial Results: In the ELEVATE IPF trial, patients receiving LYT-100 825 mg three times daily experienced a significantly slower decline in lung function, with a change in Forced Vital Capacity (FVC) of -21.5 mL at 26 weeks compared to placebo, indicating its potential in treating idiopathic pulmonary fibrosis.
Market Demand and Strategic Importance: With only about 25% of idiopathic pulmonary fibrosis patients having received treatment, the development of LYT-100 aims to address this unmet need, potentially providing more effective treatment options and enhancing the company's competitive position in the biopharmaceutical sector.
Future Development Plans: Celea Therapeutics plans to initiate the Phase 3 SURPASS-IPF trial in the first half of 2026 to compare LYT-100 with the existing therapy pirfenidone, which, if successful, could establish a pathway for potential market approval and further drive company growth.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy PRTC?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on PRTC

About PRTC

PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Deupirfenidone Shows Significant Efficacy in Idiopathic Pulmonary Fibrosis

Apr 02 2026Newsfilter

Significant Efficacy: In a 26-week clinical trial, deupirfenidone 825 mg TID monotherapy significantly slowed lung function decline in patients with idiopathic pulmonary fibrosis, with an adjusted mean FVC difference of 91 mL (p=0.02), approaching the lung function changes expected in healthy aging, indicating its potential in treatment.
Standard Treatment Comparison: This trial is the first industry-sponsored IPF trial to include a current standard-of-care treatment as an active comparator, enhancing the interpretability of efficacy and safety findings and laying a solid foundation for the upcoming Phase 3 SURPASS-IPF trial.
Financing Plans: PureTech's subsidiary, Celea Therapeutics, is working to complete financing to initiate the Phase 3 SURPASS-IPF trial in the first half of 2026, aiming to further validate the efficacy of deupirfenidone and push it towards becoming a new standard of care.
Drug Exposure and Tolerability: Deupirfenidone 825 mg TID showed approximately 50% greater drug exposure compared to pirfenidone 801 mg TID, yet the incidence of adverse events was similar (85.9% vs 84.1%), demonstrating its ability to enhance efficacy while maintaining good tolerability.

Seaport Therapeutics Announces Positive Clinical Data for GlyphAgo

Apr 02 2026Newsfilter

Clinical Trial Success: Seaport Therapeutics reported positive topline data from its GlyphAgo clinical trial, demonstrating a 6.8-fold increase in bioavailability compared to unmodified agomelatine, exceeding the expected 2-fold target, indicating GlyphAgo's potential in treating generalized anxiety disorder (GAD).
Good Safety Profile: GlyphAgo exhibited good tolerability across all evaluated doses in the trial, with no serious adverse events or liver-related side effects reported, enhancing its safety profile and potential market acceptance.
Follow-up Trial Plans: Based on the trial results, Seaport plans to advance GlyphAgo into two parallel clinical trials, including a Phase 2a trial to assess its potential sleep benefits in GAD patients and a registration-enabling Phase 2b randomized controlled trial, further validating its clinical application.
Platform Advantages: GlyphAgo leverages Seaport's Glyph platform to avoid first-pass liver metabolism, enhancing systemic exposure to agomelatine while reducing liver exposure risks, positioning it as a leading treatment option for GAD and addressing unmet market needs.

Seaport Therapeutics Publishes GlyphAllo Clinical Data

Mar 25 2026Newsfilter

Clinical Data Release: Seaport Therapeutics published first-in-human clinical and preclinical data for GlyphAllo™ in Science Translational Medicine, marking a significant advancement in depression treatment and potentially offering new therapeutic options for patients.
Drug Efficacy Validation: GlyphAllo demonstrated dose-dependent drug levels in healthy volunteers, with a single 375 mg dose significantly reducing salivary cortisol levels (p=0.0001), indicating its potential in alleviating acute physiological stress responses.
Clinical Trial Progress: The development of GlyphAllo has advanced to a global randomized double-blind Phase 2b clinical trial, aimed at evaluating its efficacy, safety, and tolerability in patients with major depressive disorder, further enhancing its market prospects.
Platform Technology Advantage: The successful application of the Glyph platform not only improved GlyphAllo's bioavailability but also showcased its broad applicability beyond neuropsychiatry, potentially leading to new therapeutic solutions in oncology, immunology, and metabolic diseases.

PureTech Health to Participate in Healthcare Conference

Feb 25 2026Businesswire

Executive Participation: PureTech Health's CEO Robert Lyne and Co-founder Eric Elenko will participate in the Leerink Partners Global Healthcare Conference on March 11, 2026, showcasing the company's innovations in biotherapeutics.
Webcast Availability: The presentation will be available via webcast on PureTech Health's investor website, ensuring that investors and the public can access the latest updates in real-time.
Company Strategy Overview: PureTech Health is dedicated to developing therapeutics through a capital-efficient R&D model, having successfully launched three products approved by the U.S. FDA, demonstrating its potential in the biotherapeutics sector.
Cautionary Forward-Looking Statements: The press release includes forward-looking statements, highlighting the risks and uncertainties that may affect the company's future plans and strategies, advising investors to consider relevant risk factors.

PureTech Secures Orphan Drug Designation for Deupirfenidone in IPF Treatment

Feb 19 2026Businesswire

Orphan Drug Designation: PureTech Health announced that its deupirfenidone (LYT-100) has received Orphan Drug Designation from both the FDA and European Commission for treating idiopathic pulmonary fibrosis (IPF), highlighting the drug's potential to address significant unmet medical needs in this rare disease.
Clinical Trial Results: In the global Phase 2b ELEVATE IPF trial, participants receiving deupirfenidone 825 mg three times daily experienced a significantly slower decline in lung function, with a 26-week FVC change of -21.5 mL compared to -112.5 mL for placebo, demonstrating the drug's superior efficacy.
Future Research Plans: Celea Therapeutics intends to initiate the Phase 3 SURPASS-IPF trial in the first half of 2026, comparing deupirfenidone to the existing treatment pirfenidone, with successful results potentially providing critical data for drug registration.
Broad Market Potential: As a next-generation antifibrotic, deupirfenidone may set a new standard of care for IPF and has potential applications in other fibrotic diseases, further solidifying PureTech's leadership in the biotherapeutics sector.